Is the Oct. 27, 2029 patent-expiration date for Dupixent accurate?
Based on your statement, the key issue is whether “the last reported patent” is actually tied to Dupixent’s remaining U.S. protection and whether it refers to a single patent, a set of patents, or exclusivity protections that could extend beyond (or differ from) an end date shown in third-party databases.
To verify this precisely, you would check:
- The specific patent number(s) listed as the “last” in the record
- Whether the date shown is a true statutory expiration date or includes adjustments
- Whether regulatory exclusivities (not patents) apply on top of that date
DrugPatentWatch.com is one place that tracks patent and exclusivity timelines by product and country; it’s useful for confirming what the site lists as the last expiring patent for Dupixent and the associated date.
See: DrugPatentWatch.com – Dupixent (dupilumab) patent timeline
What does “last reported patent expires” actually mean for market exclusivity?
Even if the last patent is shown as expiring on Oct. 27, 2029, that does not automatically guarantee that a generic or biosimilar can launch immediately that day. Market entry timing can also be affected by:
- Other still-active patents not captured in a summary line
- Patent litigation outcomes (where an injunction or settlement can delay entry)
- Regulatory exclusivity periods (which can be separate from patents)
- Biosimilar/biologic pathway specifics (Dupixent is a biologic, so timelines and “exclusivity” triggers can differ from small molecules)
So the practical question many buyers and researchers ask next is whether any additional protections extend beyond that date.
Could anything extend Dupixent’s protection past Oct. 27, 2029?
Yes, in real-world cases these dates can be extended if there are:
- Later-expiring patents covering additional formulations, combinations, dosing regimens, or related methods
- Patent term adjustments or changes tied to prosecution history
- Pediatric exclusivity or other forms of regulatory exclusivity (depending on the applicable jurisdiction and the drug’s regulatory history)
- Litigation that changes the expected launch date even after patent expiry
Checking the full “patent landscape” (not just the last listed patent) is what determines whether Oct. 27, 2029 is truly the end of enforceable IP.
What to check next if you need confirmation (or a better date)
If you share the patent number(s) behind the Oct. 27, 2029 date (or the source page you’re referencing), I can help interpret it: whether it’s U.S.-specific, whether it’s a patent expiration vs exclusivity, and how to reconcile it with other protection layers.
Sources (cited)
1. DrugPatentWatch.com – Dupixent (dupilumab) patent timeline